2020
Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST.
Goldmacher G, Khilnani A, Andtbacka R, Luke J, Hodi F, Marabelle A, Harrington K, Perrone A, Tse A, Madoff D, Schwartz L. Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. Journal Of Clinical Oncology 2020, 38: 3141-3141. DOI: 10.1200/jco.2020.38.15_suppl.3141.Peer-Reviewed Original ResearchLesion responseResponse assessmentIntratumoral immunotherapySolid tumorsTarget lesion responseModification of therapyResponse Evaluation CriteriaRoutine clinical practiceOverall response assessmentUnique treatment strategyInjected lesionsIT drugsRECIST 1.1Immunotherapy trialsNew lesionsTumor burdenMetastatic melanomaTrial protocolClinical trialsInitial progressionTreatment strategiesTherapeutic modalitiesLesion assessmentNadir valuesTreatment evolves
2010
Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progression
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survival